#Switzerland #Basel #CordenPharma #Peptide Manufacturing

CordenPharma Announces Ambitious Expansion Plans

In a bold move to enhance its manufacturing prowess, CordenPharma has declared an investment exceeding €1 billion within the next three years, focusing on the development and expansion of peptide production facilities both in Europe and the United States. Amidst this strategic growth, the company is rolling out plans to establish a greenfield facility in Muttenz, located near Basel, Switzerland, with an allocation of more than €500 million dedicated to the project.

Strategic Location: Muttenz

CordenPharma strategically selected the industrial park in Muttenz for its new facility, situated just 8 kilometers from Basel—a recognized hub for the pharmaceutical and biotech industries in Europe. This location is backed by significant advantages, including:

• - Robust infrastructure: The existing systems in place are optimized for the specific needs of peptide manufacturing.
• - Logistical efficiency: The site boasts easy access to key transportation networks.
• - Utility availability: Established large-scale utilities will support the chemical manufacturing processes involved in peptide production.
• - Access to talent: The proximity to Basel ensures a skilled workforce is readily available, feeding into the local industry’s demands.
• - Sustainability focus: The site's design emphasizes sustainable operational methods, including energy and material recycling, contributing to a long-term vision of achieving net-zero emissions.

The new facility will feature multiple manufacturing lines adept at producing peptides across various scales. This includes Solid Phase Peptide Synthesis (SPPS) reactors, specifically designed to cater to both GLP-1 and non-GLP-1 peptide projects, with an overall capacity surpassing 5,000 liters. This facility is expected to adhere to stringent manufacturing regulations, ensuring compliance with the latest industry standards.

Expanding Production Capacity in the U.S.

CordenPharma is equally committed to expanding its capabilities in the U.S., specifically at its Colorado facility. This expansion aims to double the existing SPPS reactor capacity by adding an additional 25,000 liters, bringing the total capacity to more than 42,000 liters by the year 2028. The concurrent expansions in both Switzerland and Colorado will significantly bolster CordenPharma's production capabilities in the highly competitive peptide manufacturing sector.

Dr. Michael Quirmbach, President and CEO of CordenPharma Group, expressed enthusiasm about the new plant, emphasizing the intention to create a flexible production environment that can respond to the increasing demand for innovative peptide medications. Furthermore, the company's initiatives are projected to create over 300 new jobs, contributing positively to the local economy and enhancing regional innovation.

Investing for Future Growth

The investment marks a pivotal moment for CordenPharma as it seeks to surpass the €1 billion sales milestone by 2028. This endeavor will not only solidify its position as a prominent player in the peptide sector but will also enhance the overall capabilities in the contract development and manufacturing organization (CDMO) landscape.

Judith Charpentier, Co-Head of Flagship Fund at Astorg, a private equity firm that acquired CordenPharma in 2022, commented on the importance of this strategic growth. She highlighted that Astorg is fully committed to supporting CordenPharma’s efforts to meet the increased demand for peptide production, ensuring broader access for patients who rely on life-saving peptide medicines.

Conclusion

With a firm commitment to innovation and expansion in the peptide space, CordenPharma is well-positioned to lead the industry forward. The combination of state-of-the-art infrastructure in Switzerland and expanded capabilities in the U.S. underscores their robust approach to meeting the global challenges of drug development. As the company embarks on this ambitious journey, the peptide manufacturing sector looks to grow alongside CordenPharma’s vision for the future.

For more detailed information on CordenPharma and its initiatives, please visit CordenPharma.